Hemostats Market Size & Share, by Usability (Disposable Hemostats, Reusable Hemostats); End user; Distribution Channel; Product Type; Formulation; Application - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Hemostats Market - Regional Analysis

North America Market Insights

North America is the largest and dominating market, and is expected to hold the regional revenue share of 38.7% by 2035. The market is defined by the high procedural volume, premium product adoption, and strong regulatory oversight. The key drivers include an aging population requiring complex surgeries, a robust shift to outpatient settings like ASCs, and a focus on value-based care that prioritizes technologies reducing complications and overall costs. Further, the primary trend is the integration of the hemostats into consolidated surgical suites and procedural bundles offered by major medical device companies, making standalone market entry challenging. Growth is further driven by the intense price negotiation from Group Purchasing Organizations and evolving Medicare reimbursement policies that reduce the cost-effectiveness of new technologies.

The rising trauma mortality risks and government-tracked surgical volumes in the U.S. are driving the market in U.S. According to the NLM May 2025 study, the hemorrhage is the leading cause of preventable death, accounting for nearly 43% of trauma-related deaths in civilian settings and up to 90% in combat environments, indicating a sustained federal investment in rapid bleeding control across emergency and hospital care systems. Moreover, the NLM April 2023 study has reported that over 2.8 million hip and knee arthroplasty procedures occurred in 2022, showing a 14% YoY increase, signaling high-volume orthopedic procedures where intraoperative bleeding control is routine. On the other hand, the recent advancements and clinical adoption are further supported by FDA-regulated innovation; for example, ETHIZIA Hemostatic Sealing Patch received U.S. regulatory clearance in November 2023, reflecting hospital demand for adjunct solutions that reduce operative bleeding and complications, and boosting the market growth.

Recent FDA Approvals and Clearances for Advanced Hemostatic Products

Source: Artivion, Inc, Cresilon, Inc, Medcura

The publicly funded surgical volumes, trauma care utilization, and sustained federal and provincial healthcare spending are the key drivers for the growth in the Hemostats market in Canada. According to the NLM May 2023 study Canada hospitals performed over 2 million inpatient surgical procedures, with the cost of USD 60 million, with orthopedic, cardiovascular, and general surgeries accounting for a significant share of cases requiring intraoperative bleeding control. Further, the rising health expenditure, with hospital care remaining the largest spending category under provincial budgets. Trauma-related demand also remains structurally relevant in the market. As stated in the article of the Government of Canada in June 2022, the injury-related hospitalization accounts for 225,208 cases, sustaining emergency surgical and hemorrhage management needs within publicly operated trauma centers, thereby denoting a positive market growth.

APAC Market Insights

The Asia Pacific hemostats market is growing rapidly and is expected to grow at a CAGR of 8.1% during the forecast period 2026 to 2035. The market is defined as having high growth potential driven by the expanding healthcare infrastructure, rising surgical volumes, and increasing healthcare expenditure. The key drivers include large populations with growing access to insurance, government-led healthcare modernization initiatives, and rising disease burden requiring surgical intervention. Further, the region presents a highly fragmented landscape with varying regulatory pathways price sensitive and technological adoption. Growth is propelled by the expansion of medical tourism hubs and the strategic focus of multinational corporations on customizing the products and pricing for specific APAC markets.

The expanding government-funded surgical access trauma burden and sustained public healthcare investment are driving the market in India. According to the NLM January 2024 study, India performs over 1385.28 and 355.94 per 100 000 surgical procedures annually, with a significant proportion occurring in public hospitals under national health programs. Moreover, the government schemes are increasing surgical throughput in secondary and tertiary care facilities. Further, the trauma-related demand reinforces baseline consumption, as the Petroleum and Natural Gas Regulatory Board in September 2024 reports over 460,000 road accidents and approximately 168,000 fatalities in 2022, many requiring emergency surgical intervention and hemorrhage control. Together, these data show there is a suitable upliftment of the country’s market growth.

The hemostats market in China is supported by large-scale, government-funded surgical volumes, expanding hospital infrastructure, and rapid population aging. As stated in the NLM February 2025 study, the annual day surgeries increased over 1.25 million, reflecting sustained procedural demand within public hospitals where bleeding control products are routinely utilized. Moreover, the World Bank's December 2025 data depicts that China reported that national healthcare expenditure exceeded 5.37% of the GDP in 2022, with public financing accounting for the majority of hospital service funding. On the other hand, the People’s Republic of China, October 2024 article reports that China’s population aged 60 and above reached 297 million in 2023, increasing the incidence of orthopedic, cardiovascular, and oncologic surgeries that require effective hemorrhage management, hence boosting the market growth.

Europe Market Insights

The hemostats market in Europe is expanding rapidly due to regulatory harmonization under the Medical Device Regulation, an aging population, and driving surgical volumes. Further, the growth is driven by the increasing prevalence of chronic disease requiring surgical intervention and the expansion of minimally invasive procedures, which require reliable topical hemostats. Moreover, the major trend is the increasing centralization of procurement via regional and national tenders, supporting the large suppliers with comprehensive portfolios. However, pricing pressure remains intense, with reimbursement decisions increasingly tied to health technology assessment (HTA) outcomes that demand robust clinical and economic evidence for new products.

High orthopedic surgical intensity and a rapidly aging population are the main drivers for the market growth in Germany. According to the NLM September 2023 study, Germany recorded 310.6 hip replacement procedures per 100,000 population, the highest rate among OECD countries and significantly above the OECD average of 191.5 per 100,000, indicating structurally elevated demand for intraoperative bleeding control in publicly reimbursed arthroplasty procedures. As per the Destatis data in December 2022, the Federal Statistical Office of Germany projects that the population aged 67 years and over will increase by approximately 4 million, reaching at least 20 million by the mid-2030s, driving a higher incidence of degenerative joint disease and elective joint replacement surgeries. As hip and knee arthroplasty procedures require adjunct hemostatic agents to manage blood loss and reduce transfusion risk, these trends indicate that hemostats market in Germany is set to experience an active growth opportunity.

The universal healthcare system and the rebound of publicly funded elective orthopedic procedures within the National Health Service are driving the market in UK. According to the British Orthopedic Association article in May 2022, over 42,000 orthopedic operations were performed in March 2022, the highest monthly volume since 2021, signaling renewed momentum in elective surgical activity despite winter capacity constraints. Moreover, the pre-pandemic baseline is approximately 48,500 orthopedic procedures per month. This recovery phase indicates sustained procurement of surgical consumables, including hemostatic agents, as hospitals address surgical backlogs. Orthopedic surgeries, particularly hip and knee replacements, are among the most bleeding-intensive elective procedures funded by the NHS.